论文部分内容阅读
为比较洛之达和舒降之的调脂强度，将６３例原发性高胆固醇血症患者随机分为洛之达组和舒降之组，观察服药前及服药后４周，８周血脂水平的变化。结果发现，服药４周、８周末，洛之达组和舒降之组血清总胆固醇、低密度脂蛋白胆固醇和载脂蛋白Ｂ均较治疗前有显著性降低（Ｐ＜０．０１）。洛之达降胆固醇的强度较舒降之弱。用药后两组甘油三酯水平显著降低（Ｐ＜０．０５），高密度脂蛋白胆固醇趋于升高，但无统计学意义，服药８周末洛之达组载脂蛋白ＡＩ显著升高（Ｐ＜０．０１）。患者对洛之达和舒降之的耐受性良好，无明显不良反应。结论提示，舒降之和洛之达可有效调节脂质代谢紊乱，洛之达是一种安全有效的国产血脂调节剂。
63 patients with primary hypercholesterolemia were randomly divided into losartan group and Shuzheng group to compare the lipid-lowering intensity of loxodipine and xuzheng. The levels of serum lipids Horizontal changes. The results showed that serum total cholesterol, low density lipoprotein cholesterol and apolipoprotein B were significantly decreased (P <0.01) compared with those before treatment in Losudan and Shuzheng groups. Luo of cholesterol-lowering strength than Shu-weak. After treatment, triglyceride levels decreased significantly in both groups (P <0.05), and HDL cholesterol tended to increase, but there was no statistical significance. Apolipoprotein AI in Losudan group was significantly increased at the end of the 8th week (P <0.01). Patients on the Los and comfort of good tolerance, no significant adverse reactions. Conclusions suggest that the sum of Shuzheng and Luo Zhida can effectively regulate lipid metabolism disorders, Luo Zhida is a safe and effective home-made lipid regulators.